Concord Biotech’s Share Price Drops 17%; Q3 FY25 Profit Down 2% YoY

Concord Biotech’s Q3 FY25 net profit drops by 2% to ₹75.92 crore, while revenue from operations increases by 1.4%. The company’s EBITDA falls 8%, leading to a 15.02%, the company said in a press release on the stock exchanges.

Concord Biotech’s Q3 FY25 Financial Highlights

The profit stood at ₹75.92 crore in Q3 FY25, down from ₹77.57 crore in the same quarter last year.

The company’s revenue from operations saw a modest increase of 1.4% year-on-year, amounting to ₹244.22 crore in Q3 FY25. However, its profit before tax (PBT) showed a slight decline of 2.13%, reaching ₹75.92 crore for the quarter.

EBITDA also witnessed a decline of 8%, dropping to ₹98 crore compared to ₹105.9 crore in the previous year’s quarter. This led to a reduction in the EBITDA margin by 390 basis points to 40.1% in Q3 FY25, compared to 44% in Q3 FY24.

Concord Biotech Remains Optimistic About Growth

The revenue from the Active Pharmaceutical Ingredients (API) segment grew by 3%, totalLing ₹176.6 crore, while revenue from the formulation business declined by 1% to ₹67.6 crore. The API segment now accounts for 72% of the total revenue, while the formulation business makes up 28%.

Despite these results, Concord Biotech remains optimistic about its future growth. The company expects continued growth in both the API and formulation segments, driven by new product additions and expanding customer bases.

The company is also exploring Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) opportunities with global customers.

Concord Biotech, a research-driven biopharma company, is a leading developer and manufacturer of select fermentation-based APIs, particularly in immunosuppressants and oncology. Despite the short-term setback, the company remains confident in achieving a 25% compound annual growth rate (CAGR) over the next 5 years.

Share Price Performance

Concord Biotech Limited’s share price has witnessed a significant decline, dropping by 19.70% to ₹1,695.70 at 1:35 PM on the NSE as of February 14, 2025, from a previous close of ₹2,111.70. The stock opened at ₹2,000 and hit a low of ₹1,689.40 during the trading session.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.